ࡱ> (*%&'g /bjbj xqbxqb2y> > Db|===${ZĽ=r9T=|==Ľٽccc= *R(c=ccڹh|"2[IbIL0LK 228j ==c=====ĽĽW( ================> B :    Eyegate Pharma (EYEG-NASDAQ)   Current Price (09/28/21)$1.91Valuation OUTLOOK Analyst must write  SUMMARY DATA 52-Week High$7.6852-Week Low$1.48One-Year Return (%)-51.15Beta1.10Average Daily Volume (sh)2,010,040Shares Outstanding (mil)13Market Capitalization ($mil)$24Short Interest Ratio (days)N/AInstitutional Ownership (%)56Insider Ownership (%)58Annual Cash Dividend $0.00Dividend Yield (%) 0.005-Yr. Historical Growth Rates Sales (%)N/A Earnings Per Share (%)N/A Dividend (%) N/AP/E using TTM EPSN/AP/E using 2021 Estimate-1.5P/E using 2022 Estimate-2.0Zacks RankN/A Risk LevelHigh,Type of StockSmall-ValueIndustryMed-DrugsZacks Rank in IndustryN/A  KEY POINTS Analyst must write  OVERVIEW Analyst must write  INDUSTRY OUTLOOK INDUSTRY OUTLOOK - POSITIVE Our outlook for the drug-biotech group is positive. There are a number of strong secular growth drivers that still power the pharmaceutical industry-namely, an aging population and an enormous research and development (R&D) effort to bring new, better drugs to market. People are living longer, and many have prescription pharmaceuticals to thank for it. Recent breakthroughs in oncology, neurology, and cardiology offer sizable market opportunities. Biotechnology research is finally starting to deliver. Expanded knowledge of genomics and proteomics is attracting significant attention from some of the industry's larger players. Drug companies are finding ways to reformulate and enhance current products. This is clearly a positive for the group. We expect further consolidation throughout the industry. Specifically, we see smaller specialty and generic pharmaceutical companies getting together in an attempt to create scale. This should better allow these companies to compete with the large-cap players. In the large-cap space, we are pleased to see rationalization finally starting to take hold. Companies are divesting slower growth divisions or products, and focusing more on R&D. Bloated sales forces and marketing budgets are also being reigned in to streamline costs and improve margins. Biotechnology should deliver the next wave of pharmaceutical products to the market. This should allow the group to outperform the broader sector. Thanks to favorable tax legislation and low debt levels, large pharmaceutical companies are in excellent position to acquire their smaller biotechnology brethren. We would be buyers of large profitable biotechnology stocks, as well as small-cap biotechnology stocks with promising pipelines. Performance of the large pharmaceutical group has been poor the past five years, but we believe these companies should have a meaningfully better second half of the decade. Most now offer low valuations and significant turnaround potential.  INDUSTRY POSITION Analyst must write   RECENT NEWS Analyst must write  VALUATION Analyst must write   RISKS Analyst must write.  INSIDER TRADING AND OWNERSHIP Analyst must write.  PROJECTED INCOME STATEMENT & BALANCE SHEET   Historical Stock Price   DISCLOSURES The following disclosures relate to relationships between Zacks Small-Cap Research (Zacks SCR), a division of Zacks Investment Research (ZIR), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES I, Elizabeth Senko, Senior Analyst, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice. INVESTMENT BANKING AND FEES FOR SERVICES Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request. POLICY DISCLOSURES This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuers business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article. ADDITIONAL INFORMATION Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned. CANADIAN COVERAGE This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.       Month Day, Year Zacks Small-Cap Research Elizabeth Senko, Senior Analyst 312-265-xxxx email@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Sponsored Impartial - Comprehensive Sponsored Impartial - Comprehensive EYEG: Zacks Company Report Text ZACKS ESTIMATES Revenue (in millions of $) Q1Q2Q3Q4Year(Mar)(Jun)(Sep)(Dec)(Dec)20193 A   3 A2020   0 A0 A2021     2022      Price/Sales Ratio (Industry = 2.5x) Q1Q2Q3Q4Year(Mar)(Jun)(Sep)(Dec)(Dec)2019$0.15 A-$0.60 A-$1.15 A-$0.76 A-$2.23 A2020-$0.43 A-$0.38 A-$0.44 A-$0.52 A-$1.77 A2021-$0.37 A-$0.35 A-$0.29 E-$0.23 E-$1.24 E2022-$0.25 E-$0.23 E  -$0.94 E Zacks Projected EPS Growth Rate - Next 5 Years %N/AN/AN/A Top 5 Public Companies in the industryTickerCompanyMarket ShareZacksRecTKPYYTakeda Pharmact19.27766N/AMKGAFMerck Kgaa14.91029HoldALPMYAstellas Pharma12.82172HoldVRXValeant Pharma9.57371BuySHPGShire Plc-Adr6.97693Hold Industry Comparables Pr Chg YTDP/E CurrFY EPS Gr 5Yr EstPrice/ BookPrice/ SalesPrice/ CFEYEGATE PHARMA-61.31.3Industry Mean0.00.00.00.00.00.0Industry Median0.00.00.00.00.00.0S&P 500 15.922.914.00.032.0ALDEYRA THERAPT28.42.2FUSION PHARMACT-31.11.3 Eyegate Pharma Income Statement and Balance Sheet(Dollars in millions, except EPS data)12/1612/1712/18N/A12/2012/21ESales10230N/ACost of Goods Sold00000N/ASG&A65445N/AOther operating expenses810854N/AInterest and other0-1000N/AZacks Adjusted Income before NRI-13-15-11-7-8-16Net Income-13-13-11-7-8-16Diluted EPS before NRI-22.64-15.29-4.50-2.23-1.77-1.24Reported EPS-22.64-13.94-4.50-2.23-1.77-1.24Cash & Marketable Securities488411Current Assets488422Current Liabilities7154122Long Term Debt000000Shareholder's Equity0-2977-9  Zacks Investment Research Page  PAGE 2 scr.zacks.com Copyright  DATE \@ "yyyy" \* MERGEFORMAT 2021, Zacks Investment Research. All Rights Reserved.  (+,023:RSXYZefĮ{r]rSISI>h5CJOJQJhCJOJQJhmCJOJQJ)jh5OJQJUmHnHtHuh5OJQJ%jh5OJQJUmHnHuh5B*OJQJphhm5B*OJQJphhhm"hB*OJQJmHnHphuh5B*CJ(OJQJph)jh5CJ@OJQJUmHnHu+jhB*OJQJUmHnHphu  )*+-./0zvkd$$Ifl_0Z t04 la$If$If012456789:SYZdeOkd$$Ifl#0Z N b t4 la $$Ifa$$Ifefgo:ckdZ$$IflQ  t04 la$U&#$/IfOkd$$Ifl#0Z N b t4 lafo # % D G e h   / 2 G J a d f } ~ h5CJOJQJ)jh5CJOJQJUmHnHuhm5CJOJQJh5CJOJQJhB*phhh5CJOJQJhCJOJQJhmCJOJQJh5OJQJ:Gkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/If B & NGkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd1$$Ifl0 H 4 la   NGkd<$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd$$Ifl0 H 4 la # & ' D H NGkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd$$Ifl0 H 4 laH I e i j NGkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkdG$$Ifl0 H 4 la NGkdR$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd$$Ifl0 H 4 la NGkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd$$Ifl0 H 4 la NGkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd]$$Ifl0 H 4 la     / 3 NGkdh$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd$$Ifl0 H 4 la3 4 G K L M N NGkd$$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd$$Ifl0 H 4 laN O a e f ~ NGkd$$Ifl80 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkds$$Ifl0 H 4 la NGkd~ $$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd% $$Ifle0 H 4 la NGkd0 $$Ifl0 H 4 la$$~&`#$/Ifa$$~&`#$/IfGkd $$Ifl0 H 4 la VGkd $$Ifl0\  4 la  $$Ifa$ $If^h^hGkd $$Ifl0 H 4 la   \Gkd $$Ifl0\  4 la  $$Ifa$ $If^Gkd@ $$Ifl)0\  4 la      1 3 E F [ \ b d g v ҿۣҕ{oea{UKhCJOJQJhCJOJQJaJhhmCJOJQJhCJOJQJaJ"jhCJUaJmHnHuhOJQJhB*CJOJQJphhOJQJhOJQJ\hCJOJQJ\%jh5OJQJUmHnHuh5OJQJjhUmHnHuhm5CJOJQJh5CJOJQJ         ! " # $ % & ' ( ) * + h^hGkd $$Ifl0\  4 la + , - . / 0 1 4 E F [ \ ] ^ _ ` a b g u v ^ h^h & F>^`> >^`>h^h h^hh^h  @^^^h^h 68:K`avxy.06MNOfhoz{tĺĺĺĺĒć{mhCJOJQJ^JaJjZ hmOJQJUh5;OJQJ%jh5OJQJUmHnHuhCJOJQJh5CJOJQJhCJOJQJh5OJQJhmHnHujhUmHnHuhOJQJ&jhCJOJQJUmHnHu& ./01234569d^h^h9JK^_`bcopqrstuvy$^a$$ & F>^`>a$ ^^h^h !"^h^h"#$%&'()*+,-.1MNPQRSTUVWXYZ[\h^h^\]^_`abcdei{|\]q&\]r( ^m$ dd^m$^h^ht2&3&5&6&8&9&;&<&>&@&B&D&G&Z&[&\&]&^&&&&&&&''-'غءo]]Mh6B*OJQJ^Jph"h5B*CJOJQJaJphhm5B*CJOJQJphh5B*CJ(OJQJph"h5B*CJOJQJaJphh5CJOJQJhB*CJOJQJphh5B*CJOJQJphjhUmHnHuhjhUhCJOJQJ^JaJhmCJOJQJ^JaJ ###1&2&4&5&7&8&:&;&=&>&A&B&E&F&G&Z&[&\&]&^&$a$^ dd^^m$ dd^m$^&&&&&''-'.'U'V'r's'y'z''''''''' $$Ifa$$a$  $P^P`a$ ^` P^P`-'.'/'T'V'q'r'z''''''''''''''''''''''''''''''''''''((((( ( (·}}}}}}}}}}}}}}}}}hmCJOJQJhCJOJQJ hCJh5CJOJQJhCJOJQJh5CJOJQJh5CJ OJQJh5OJQJh5OJQJ^Jhm5OJQJ^Jh6CJ]aJhh6B*OJQJ^Jph1''''''''''bkdC$$Iflֈ_ OH&*4 la $$Ifa$ ''''''''kbYYYYY $$Ifa$ $$Ifa$kdD$$Iflֈ_ OH&*4 la''''(( ( (kbYYYYY $$Ifa$ $$Ifa$kdE$$Iflֈ_ OH&*4 la ( (((((((((("(#(&('(((,(-(0(1(4(5(8(9(<(=(@(A(B(D(h(i({(|(}(((((((((((((((((((((((((((((((((((())))Ĺh5CJOJQJh5CJOJQJaJh5CJOJQJhCJOJQJhmCJOJQJ hCJhCJOJQJI ((((((#('(kbYYYYY $$Ifa$ $$Ifa$kdE$$Iflֈ_ OH&*4 la'(((-(1(5(9(=(A(kbYYYYY $$Ifa$ $$Ifa$kdWF$$Iflֈ_ OH&*4 laA(B(D(h(i(j(m(p(s(v({(kiii`````` $$Ifa$kdF$$Iflֈ_ OH&*4 la {(|(}((((((f]]]]]] $$Ifa$kdG$$Iflֈq OH&vw4 la((((((((fYPPPPP $$Ifa$ $$If]a$kdH$$Iflֈq OH&vw4 la((((((()fYPPPPP $$Ifa$ $$If]a$kdH$$Iflֈq OH&vw4 la)))))!)*)3)fYPPPPP $$Ifa$ $$If]a$kd-I$$Iflֈq OH&vw4 la))))) )!)))*)2)3)4)8)9)A)B)J)K)N)O)R)S)[)\)])_))))))))))))))))))))ƻƻܷ~qh5CJOJPJQJ!h56B*CJOJQJphhB*CJOJQJphh5B*CJOJQJphhCJOJQJhh5CJOJQJh5CJOJQJhm5CJOJQJhCJOJQJ hCJhCJOJQJhmCJOJQJ,3)4)9)B)K)O)S)\)fYPPPPP $$Ifa$ $$If]a$kdI$$Iflֈq OH&vw4 la\)])_)))fd^U $$Ifa$$IfkdIJ$$Iflֈq OH&vw4 la))))))))`^^U $$Ifa$Gkd/K$$Ifl)0& v4 la $$Ifa$$IfGkdJ$$Ifl)0& v4 la))))))))EqkdK$$IfTl\  34 laT $$Ifa$$If8kdK$$IfTlL4 laT)))))))))~qkdOL$$IfTl\  34 laT $$Ifa$$If))))))*******"*#*$*)***4*5*=*>*B*C*D*I*J*Y*Z*b*c*g*h*i*l*m*{*|*******************̼̼̼̼̼̼̼̼̼̼̼̼̼̼̼̼̼̼̼̼賩hCJOJQJhhCJOJQJh5OJQJhB*CJOJQJhphhmB*CJOJQJhphhCJOJPJQJ hCJ!h56B*CJOJQJph7)****#*~$If $$Ifa$qkdL$$IfTl\  34 laT#*$***5*>*C*~$If $$Ifa$qkd[M$$IfTl\  34 laTC*D*J*Z*c*h*~$If $$Ifa$qkdM$$IfTl\  34 laTh*i*m*|***~$If $$Ifa$qkdAN$$IfTl\  34 laT******~$If $$Ifa$qkdN$$IfTl\  34 laT*************{rrii $$Ifa$ $$Ifa$$If &dPqkd'O$$IfTl\  34 laT **++++#+&+)+,+-+4+5+C+F+G+J+K+N+O+R+S+V+W+Z+[+\+l+o+p+s+t+w+x+{+|+++++++++++++++++++++++++++++++++;ܪܪܪܪܪܴܴhCJOJQJhmCJOJQJh5CJOJQJ^JaJhm5CJOJQJ^JaJhh5CJOJQJ(h5CJOJQJ^JaJmHnHuC******+ ++ $$Ifa$ $$Ifa$+++$+%+&+*+LF==== $$Ifa$$IfkdO$$Ifl֞ D=6/ t644 la*+++,+-+.+/+0+C=$IfkdO$$Ifl֞ D=6/ t644 la $$Ifa$0+1+2+3+4+5+C+C=$IfkdXP$$Ifl֞ D=6/ t644 la $$Ifa$C+G+K+O+S+W+[+\+CkdP$$Ifl֞ D=6/ t644 la $$Ifa$\+l+p+t+x+|+++ $$Ifa$$If+++++++LF==== $$Ifa$$IfkdQ$$Ifl֞ D=6/ t644 la+++++++C=$IfkduQ$$Ifl֞ D=6/ t644 la $$Ifa$+++++++C=$IfkdQ$$Ifl֞ D=6/ t644 la $$Ifa$++++++++Ckd3R$$Ifl֞ D=6/ t644 la $$Ifa$++++++++ $$Ifa$$If+++++++LF==== $$Ifa$$IfkdR$$Ifl֞ D=6/ t644 la++++++,, ,,,,@,C,j,q,w,x,y,~,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ɝ||||||||hmB*CJOJQJhph!h5B*CJOJQJhph!hm5B*CJOJQJhphhB*CJOJQJhphh6CJOJQJh5CJOJQJhCJOJQJhmCJOJQJhCJOJQJhCJOJQJh0+++++++C=$IfkdR$$Ifl֞ D=6/ t644 la $$Ifa$+++++++C=$IfkdPS$$Ifl֞ D=6/ t644 la $$Ifa$++,,,,,,CkdS$$Ifl֞ D=6/ t644 la $$Ifa$,,, ,,,,@,B,C,VKkdkT$$IfTl0W"4 laTKkdT$$IfTl0W"4 laT $$Ifa$$If C,j,l,m,o,p,q,r,s,t,u,v,w,KkdT$$IfTl0W"4 laT $$Ifa$$If w,x,y,,,.%%% $$Ifa$kd%U$$IfTl # w W"<Si8888$$$$4 laT,,,,,,,,KE$IfkdU$$IfTl֞ w W" 88884 laT $$Ifa$,,,,,,, $$Ifa$,,,,,,A8288$If $$Ifa$kdOV$$IfTlִ w W"t8888    4 laT,,,,,,,,,,,,,,,,,,,,,,- - - - -----------.-/-1-2-3-4-5-6-7-8-;-<-^-a-b-e-f-i-j-l-m-o-p-s-t-u--------------------h5CJOJQJhCJOJQJhB*CJOJQJhphhmB*CJOJQJhphP,,,,,,,8kdV$$IfTlִ w W"<8888    4 laT $$Ifa$,,,,,,,, $$Ifa$$If,,,- - -A8288$If $$Ifa$kd]W$$IfTlִ w W"<8888    4 laT -------8kdW$$IfTlִ w W"<8888    4 laT $$Ifa$---/-2-4-6-8-<- $$Ifa$$If<-=-^-b-f-j-A;222 $$Ifa$$IfkdkX$$IfTlִ w W"<8888    4 laTj-m-p-t-u----KE$IfkdX$$IfTl֞ w W" 88884 laT $$Ifa$--------KE$IfkdkY$$IfTl֞ w W" 88884 laT $$Ifa$--------KE$IfkdY$$IfTl֞ w W" 88884 laT $$Ifa$--------------------.... ../.0.1.2.3.4.5.6.7.8.9.:.;.K.L.M.N.O.P.Q.R.S.T.U.V.W.l.m.n.p.q.r.s.t.u.v.w.x.y.................h5CJOJQJhCJOJQJhB*CJOJQJhphhmB*CJOJQJhphP-----.. . .Kkd]Z$$IfTl֞ w W" 88884 laT $$Ifa$ . . ......KkdZ$$IfTl֞ w W" 88884 laT $$Ifa$./.1.3.5.7.9.;. $$Ifa$$If;.<.K.M.O.Q.S.U.TNEEEEE $$Ifa$$IfkdO[$$IfTl֞ w W" 88884 laTU.W.X.l.n.q.s.u.KE$Ifkd[$$IfTl֞ w W" 88884 laT $$Ifa$u.w.y.z.....KE$IfkdA\$$IfTl֞ w W" 88884 laT $$Ifa$........KE$Ifkd\$$IfTl֞ w W" 88884 laT $$Ifa$................/ / /////P/^/_/k/l///ÿ֔uc֤UUjhCJOJQJU"jh0JCJOJQJU*$hm0JCJOJQJmHnHu*h0JCJOJQJjh0JCJOJQJUh5CJOJQJj]h5CJOJQJUhhCJOJQJh5OJQJhCJOJQJhB*CJOJQJhphhmB*CJOJQJhph.........KIIIkd3]$$IfTl֞ w W" 88884 laT $$Ifa$.....^/_///// //////hCJOJQJ^JaJhhCJOJQJjhCJOJQJUhmCJOJQJmHnHu= 0P&P1h/ =!z"z#$8% Dp= 0P&P1h/ =!z"v#$8% DpA 0P&P1h/ =!z"v#$8% P Dp@ 0 0P&P1h/ =!z"z#$8% Dp$$If!vh#vZ#v :V l_ t0,5Z5 4b$$If!vh#vN #vb:V l# t,5N 5b4ab$$If!vh#vN #vb:V l# t,5N 5b4a|$$If!vh#v:V lQ t054W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l8,5 54W$$If!vh#v #v:V le,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54W$$If!vh#v #v:V l,5 54\$$If !vh#v\ #v :V l,5\ 5 4a \$$If !vh#v\ #v :V l),5\ 5 4a \$$If !vh#v\ #v :V l,5\ 5 4a \$$If !vh#v\ #v :V l,5\ 5 4a 7Dd,pF  C "A EYEGb6T&r36 n6T&r3PNG  IHDRT IDATx?oLᳫ )8+CJ4)iVHDSD@$ %}FJMKPf- Ā1lR 1fZ H,X$: V+ܤ?}.ki{R$f,Ldr""b50;sԮ_scno7)1F_>sv׏|VgJ3-]^d *=GSR"b3aGD2dFU+5U:=[ Jͅ)˗uDD$JצޮǑjRgYљ yߣt11;͞m]˧fK*O|e(3]In6*ZNMwbė2+7JuJ՞ԕJO Mn׿jݎ#׬=];uN/v+wR]kgv$ gK1DݓU+W *"EDҵY%.'"AXYu/&{bBD9nMKҎѥHU:r;Gv+yʑ1U:2VZ>jCGϏu?qnd a2UOᆰtϵe?Lz~QOf]Z~f劗"R(=7Kx}8!H[{rpie4kJavjomH^3?SPae_'=d̶݆;ERy6㦾ɿ~6#2Z=)eI*d&4~c8&O$un$.!VcTs7l%ҵ:""b>[CD ųΓ岀p(sWZ(ߏþ9..NÇt(?#">}#2sPNK#~⼎ҥp6~s:ڑ.}?sB,ȨxRl:.Kw_Zgڋ R培J޼N;OEMz^W/󃤋$+,1J}}5sV Rf˂Oqzۺ:#Zk\w#Dvb[9} udnyY۵+12?_v7Pd9HryE$-: Ht@bՕRj/a0?/r"&BH,X$: Ht@b"ED$H,X$: Ht@b"!0Uj(Vա2wHt@к}?jW{RWZֵUiXs{Dn|[?bADĸJ;Vwޥ;!A*Ԕ֗s$sϧ&Lߥ!!{.fRjտ>b**Qɫ(FNbZRjJ֥(VJyTV+}Q*گۼKw5r}hD|ztaҝ_pp*7G݋sfZxV"*uD$H,X$: Ht@b"EG@@j9/=lT?, ZCG[~1/Gjf7t]~> "b3l:Go¡ECNEߋvh1NrﮈvJq_No[JkKtYF6KtRYlTPY'PQBM^E1 uӊR /DD$]kwZ)K2ycd<Kh=R3= 3U*]U^} qX 52N)=t_Uu8ϊ!a02PV=8k5"uF7PhTT_DDNo[a̜Dz$AB당)F/˗XED gëCF@D$H,X$: Ht@bqgd '20J'"rVwyP!Bըsujݎ>i=KJ ;s~DDrԳ27ybqwn}1|~mdfzaW$: 8I1Bp6KtRYlTPY'PQBM^E1 uӊR /DD$]kwZ)K2ysZ/Zkb +~ (U-yNuE(渟O_""F9SGo!1Nr=1N>5ՌVJ+á (]PZH>o%/˲!"v}nf-:JU, v6*ue*+*QVZx!"bjm)U\iYflڣX)=ya[L!5mȱjml6S1܁_C\686tt|sf9WUFob?biGEDNo[3E, TB당)F/˗XED$pHBEDJ)}( Ht@b"ED$2J'"rVKO|nEE+Vb]֪u;|VmԮVkҰŽ&sϧ )FsAX1 9$׳M=SRsܟM1Nr2~3$:^!x$JtfPJczqh6KtRYlTPY'PQBM^E1 uӊR /DDaU -7z:Oeh=R3˷^$}@- W6X 5̶.˟:VCYEXZݸ,+H_\ޢ p1:ҵ:rm$lJP>: HFY9m]7ޤ@Q}taD'+:WB당)FgkZKBn)$9Zv[>tXpcGcC+NM^!F]`Mt<R!Rf73>#DgS}[2 9Mth bpgdێG^^;a0/R] f8P$:a7;(_zHOd OʉYe?͞/D%: :I9=2ecaxhR =&:%c/-{mfRjտ>/!؊v\v_B*g| Tt NbZRjŧɧsDLS_NyRryEkQ!$-:r+^;F7)nN?Tr݆~*;0kֽK\'أ[-龪ϯ脍a:؛oLq3'êzHumUVJ+ &:x_AtMC62M=}NhEf5.'8':vTqe I0X@ ۉb&: }ih%0}$F69vu[BCfN#fO· ]c=xKn [Hf3SfrR/ CDa2E"bUgqMtbKEoH״9',_BV I#vY"DH20D ;$D]q`\?U O1Ntb {Fy3@D-:@b+&ѡQLUVm.Z Ҏ^@hP:T1TPWQBeĴ"‹|uezֳ39Oeh=Rfָ7#jIw]Du$"ؽ}5ʖRQ ͱjm] G "ZدC5̅Å`@o{9WsO푈V5 pY{-Ѻp$"<]XP?){/9 C7r3?PԽH>j&DGX8, $WG/]Ӫ`dzuiʍczCCac|o':y}#,b QoaD+&<qJX-:y}bE!3E9=au$DtR:&R 7b س-.#Ž؅5 0Li!b߃Y \v!~lT?O]v^\-x>JuU[x1:ZΞi|qJ pƃ}E7jt7* ctgKJQ/˲!"v}nQZtR>zW)-MEEjE jL+ 5qY'V ʡ&PC]u2{ QX'GXRjᅈiY;]/Zkb ~i1' I/ⱜ$WWaob??b73TOŕCK5ew =?Y49<~v$ag>:q͒v*\^*/""˂jet/ a":97b3ʗ0)ԫKt+vSvHctu䢳Rco^g ; E.8؅D|7O&A8;Xe]bӏYĈPX`02 W(7X HtCqιL+V.fD'tx>jgu؎R-f^Ji^V.|UxDy(W=|ԮtAKqkP @<ع습*gH4ą֊gFo7ybqwDªt8ZϷؗ+Np4 8A29 9S,8-Ht]EZ[ r.g2=iЬ;RVsܗeQ>_'}SR򿫧ki>N5((T`?.Ӭ]4q/Zuw_7=fs1nM>?Q4vp=AE(XTZx!"bdz٤>W_J'0·7a:Y)4ځZu]>x"UVI9, N݆~*:&[ eEADa2_k w~- C,5;l2:~7>zOOd#1^)j# F%9p!On)m7 ֵU_9mP'Unsҕt+ߖKD#1vFR&ezOUm_Т`K1`6@@m TL7|~D~vm٢or.u- TH$:\(-\8(D?8A+#{JtH*BbnDgEO ]"/lB-]p]j_ZM -A`IiiTw><\Hh34z<) Fo!dy!;WF_L֥h<}W&]W[#щ?WNH2(b}lrzRZ+g^fl(VlWl1(FN{6-U (, ,a{Cv.)^؝V唸22M}9́RrwEkQ?{⽻/σHeg_-D 5&c. fr!"6S1܁[ p,$Z^o/u~9jW nzHCDd?+kwH<8{2\q<Ǝ& c#κ|Ɛ@j2pѺ*+?/9-:LWT&/LSO_~6Y mX~)+|t]wõ=g [x?$:i\;W^6m $B؇c>[Rzf<}W=]PuȮ ZaUʽHOe{mfRjտ>B uCM s J`׉'q!{ݰ6^RZ (XTZx4:3̧2F/ˆO[c.(VJyπ8Ð=J!FogXfN T\9ػ4_C\6>;fw G؟8Sg~\V WEk}; Gpz{޶.ˆ9VF7TItXW}T.|HF *: 8KEEDuY67r3?PԽ}D(_¤LSI״+-^DX:;@," FY{oD$b$: HtE;##N0J'""""fr1C=It@FźnW/mqWS'bF͚s*4UPY'1H)j?ߛd#Գ!;o}Z{+gHn/OW/Zkb Z*jZayv(LfدC5̅$+kV,GDN푈V5 y Ɯ9~g'һӝR]g7r3?PԽH>j>QəN״ $:@ct3t'^Ep! F$\$:5f zo%$:3;sD^& s4x#,ϽG[N`)9=*H)f-:$HL_Xt__Gi̓ԡCD;(&/ʱIËrlBx;rlZ}mhu7.i|oD)ar,g3A2jqEGbq_No[eCDFK~/Zk(7X(a2q T wΚ4(Xv6D;(&/ʱIËrlBx;rl/WUFob?b٬pz{޶.1:EH,X$: MtvU-pqٮVnCM~ٮg(t[d!X9өˆs~8;lv۸ްۮu}nA綃mBϹ|U?mSg3yj^`xvw7KU(u?7f-齙,e!~jZ\'[3|-7=퇎۞2;Nw>+My>߁xG1q4[9΃zfյb}\x.ofu[{ qF^"8ͷ~>5^j~g :6{+N^Q1f-齙<;Mtz֊wnvUʽEq̾n&z:*``p3mLn8{'DgOc<vO[ٖ+K5.#e9?y~}V{ҹSնʙP"W7#8קk̡VȲG]aϻ=m4-])۴(vw7ytz=Dfʹgzt[|qc>=_l~6j>WG5/ "ql?x10uR]7Ɗfݨ|n$voc46tո 9Ķ[\]aϻa}Y(&Cu^dx.N;[Hv:={H;b3me彙Vܒ(~0:jjE݋H,f-FY{򷭦8ǞHNX쬮H .)OH6dMoC*2'[;>I-Eqj'tI;u촳֜\Nᇷ xEH6$alfZms˶E# @b"ED$^w]cKm ܯ_Kgx|1W缛'ϮVG̋HQ؏Zx*}y"lkr6*-=_9[&U-\miDlWݳʼnnyLoi\];O䕏wPI-n 4G>D٪}>}>(px6m[ܯSBʉqQ3m%?Ή'\|`-7}:#ͷ~>;5yˊK^N2{@5-WۙBMk:1|':$Mu[+ٺGE=靚t]M@[7yD~,@_fz׿Y6DP7Ў{e}0_5wT~wui%[i;g:{Pk얦9"x6RvU=dQ87xep"C=EN2ӇNXƷ\]/!rŕʼnӷ.HqtdJN7A/..KfJ-޺ u׿mim[ F6Tul6~hjX/svِ+[\(mL .ׯK4eڞg1ݧPs:16j ϋ_P?)Db>eyw@-_>cOwfcOKu]+|^1k޲uH_և <$也dIENDB`$$If!vh#v*#v#v#v#v#v:V l,5*555554a$$If!vh#v*#v#v#v#v#v:V l,5*555554a$$If!vh#v*#v#v#v#v#v:V l,,5*555554a$$If!vh#v*#v#v#v#v#v:V l,,5*555554a$$If!vh#v*#v#v#v#v#v:V l,,5*555554a$$If!vh#v*#v#v#v#v#v:V l,,5*555554a$$If!vh#vv#vw#v#v#v:V l,5v5w5554a$$If!vh#vv#vw#v#v#v:V l,5v5w5554a$$If!vh#vv#vw#v#v#v:V l,,5v5w5554a$$If!vh#vv#vw#v#v#v:V l,,5v5w5554a$$If!vh#vv#vw#v#v#v:V l,,5v5w5554a$$If!vh#vv#vw#v#v#v:V l,,5v5w5554aV$$If!vh#v #vv:V l)5 5v4aV$$If!vh#v #vv:V l)5 5v4aM$$If!vh#vL:V l,5L4Tw$$If!vh#v#v #v#v3:V l,55 5534T$$If!vh#v#v #v#v3:V l,,,55 5534T$$If!vh#v#v #v#v3:V l,55 553/ 4Tq$$If!vh#v#v #v#v3:V l55 5534Tq$$If!vh#v#v #v#v3:V l55 5534Tq$$If!vh#v#v #v#v3:V l55 5534Tq$$If!vh#v#v #v#v3:V l55 5534Tq$$If!vh#v#v #v#v3:V l55 5534T]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5]$$If!vh#v#vP#v#vo#v:V l t6,5[$$If!vh#v#v:V l,554T[$$If!vh#v#v:V l,554T[$$If!vh#v#v:V l,554T$$If!v h#v<#vS#vi#v#v8#v :V l, 5<5S5i5585 / 4T$$If!vh#v #v#v8#v:V l,5 5585/ 4T$$If!vh#vt#v#v#v8#v:V l,5t555854T$$If!vh#v<#v#v#v8#v:V l,5<555854T$$If!vh#v<#v#v#v8#v:V l,5<555854T$$If!vh#v<#v#v#v8#v:V l,5<555854T$$If!vh#v<#v#v#v8#v:V l,5<555854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854Tw$$If!vh#v #v#v8#v:V l,5 55854T&Dd *(0  # A"Ed=|W5'g|~]@=vEd=|W5'g|ipbDxڍTkAfvF)qڒ[ڂ 9RRAA(xڋ&DУ'={IxTbfNB||3(w,M:Q:FK(eITw?E5[;l@N)pxBPɇ{E`kMѝ71&^s93isE9!:Z[%#5k[sɟ|ֶqwq( ZӺ=:{yi!hK&"5Э| ?2@S!tg:ZR\QbcLLpu}oRo[B<^}W좟\>I7mZB>{  +a\@HxFOme /ef޽^iG|uw:_lWNpC8' P\g=g mm9o{ID/}~PGmjmx o=NxM ] ~IQ;wRs49 >c:E3v@P~Ds |w<v ,3Ygx'&#% ,3Ygx{'  +'?~ f t-' ())*+,-.//,17:>FLS`jt|0e H 3 N  + 9"\ ^&''' ('(A({((()3)\)))))#*C*h****+*+0+C+\++++++++++,C,w,,,,,,, --<-j---- ..;.U.u..../ !"#$%&'()*+-./02345689;<=?@ABCDEGHIJKMNOPQRTUVWXYZ[\]^_abcdefghiklmnopqrsuvwxyz{}~JQS !  '' 0e0e     @ 5% 8c8c     ?1 d0u0@Ty2 NP'p<'pA)BCD|E||C"x0e @       ?  4444-@ABC DEFGHIJK5%LMNOPQRSTUWYZ[ \]^_ `abN 5%  N 5%  N    5%    !"?N@ABC DEFGHIJK5%LMNOPQRSTUWYZ[ \]^_ `ab?@A BCDEF GHZZȈ@ (  hB  c $DdP8c#" ?b  3 #" ? b  3 #" ? hB  c $D8c#" ?"&`(  hB  c $D8c#" ? b  C 3"`? hB  c $D8c#" ? b  C 3"`? h  S 8c3"`?b  C 3"`?hB  c $D8c#" ?b   C 3"`?hB   c $D8c#" ?hB   c $D8c#" ? hB   c $D8c#" ? b   C 3"`?hB  c $D8c#" ?b  C 3"`?hB  c $D8c#" ?h  S 3"`?hB  c $D8c#" ?b  C 3"`?hB  c $D8c#" ?b  C 3"`?t  S 3"`? n  C 3"`? h  C #" `? hB  c $D8c#" ?t  S 3"`? hB  c $D8c#" ?b  C 3"`?t  S  3"`?  B  B D1?"6@?NNN?Nz   s *  #" `? h # # C"`? n % # S"`?  & <&?"T@`??NNN?N? B S  ?+212bc   6 7 ` v w  . / f g 'L!*tk*t&ltIi)It#`dEp%Z07tt[t @t *t@t*t*t@t*t@tpo # t*t@t@t*t F$rt*t Ot *t@t@t*tH")t@t*t@t *t xq*,t*ty*{tK+t (:RSXo#%DGeh/2GJadf}~ N O tt124578:;=>FGVq              " # & ( , - 0 1 4 5 8 9 < = @ } !!!!!!! !!!)!*!2!4!8!9!A!B!J!K!N!O!R!S![!!!!!!!"""""""""$")"*"4"5"=">"B"D"I"J"Y"Z"b"c"g"i"l"m"{"|""""""""""""""#####&#)#C#F#G#J#K#N#O#R#S#V#W#Z#l#o#p#s#t#w#x#{#|########################## $$y$~$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$% % % % %%%%%%%%-%.%/%1%2%3%4%5%6%7%8%;%^%a%b%e%f%i%j%l%m%o%p%s%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&/&0&1&2&3&4&5&6&7&8&9&:&K&L&M&N&O&P&Q&R&S&T&U&V&l&m&n&p&q&r&s&t&u&v&w&x&&&&&&&&&&&&&&&&&&&&&&&&&&& ''k'''' (:RSXo#%DGeh/2GJadf}~ N O t1& ''k''' (+:RSXo#%DGeh/2GJOadf}~14 ` c u y , 1 N O | t =124578:;=>FGZ^TVqsx              " # & ( , - 0 1 4 5 8 9 < = @ D j } !!!!!!! !!!)!*!2!4!8!9!A!B!J!K!N!O!R!S![!_!!!!!!!!"""""""""$")"*"4"5"=">"B"D"I"J"Y"Z"b"c"g"i"l"m"{"|""""""""""""""######&#)#5#C#F#G#J#K#N#O#R#S#V#W#Z#l#o#p#s#t#w#x#{#|##########################$$ $$$y$~$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$% % % % %%%%%%%%-%.%/%1%2%3%4%5%6%7%8%;%=%^%a%b%e%f%i%j%l%m%o%p%s%u%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&/&0&1&2&3&4&5&6&7&8&9&:&K&L&M&N&O&P&Q&R&S&T&U&V&l&m&n&p&q&r&s&t&u&v&w&x&&&&&&&&&&&&&&&&&&&&&&&&&&&& ''_'k''''' (29:RSXZcffo#%DGeh/2GJadf}~ , - 5 L N O e f { 1245578:;=>FG^dqsz              " # & ( , - 0 1 4 5 8 9 < = @ D h i i } !!!!!!! !!!)!*!2!4!8!9!A!B!J!K!N!O!R!S![!!!!!!!"""""""""$")"*"4"5"=">"B"D"I"J"Y"Z"b"c"g"i"l"m"{"|""""""""""""#####&#)#C#F#G#J#K#N#O#R#S#V#W#Z#l#o#p#s#t#w#x#{#|########################## $$y$~$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$% % % % %%%%%%%%-%.%/%1%2%3%4%5%6%7%8%;%^%a%b%e%f%i%j%l%m%o%p%s%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&/&0&1&2&3&4&5&6&7&8&9&:&K&L&M&N&O&P&Q&R&S&T&U&V&l&m&n&p&q&r&s&t&u&v&w&x&&&&&&&&&&&&&&&&&&&&&&&&&&'#Ug *  )y>}H 6 ZO85 zX @h+K{ > 4yx`?e& ')S"!)xZ"`j& {`})N&dA2~X7B&D9 $up? CD@]eyKbY4M:(]U(^+WZOoeZD0ZpB?`)\d)SQ;eV e)>{hr :yp^$=qu)Mayh8vh 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJ QJ o( ^`OJ QJ o( @ @ ^@ `OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o ^`OJ QJ o( PP^P`OJQJo(   ^ `OJQJo(o ^`OJ QJ o(h ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJ QJ o(h 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h^`OJ QJ o(hH ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h88^8`OJ QJ o(hHh ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h88^8`.h^`.h L ^ `L.h  ^ `.hxx^x`.hHLH^H`L.h^`.h^`.hL^`L.h^`OJ QJ o(hH ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJ QJ o(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJ QJ o(h 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o( ^`OJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h ^`OJQJo(h   ^ `OJQJo(oh   ^ `OJ QJ o(h xx^x`OJQJo(h HH^H`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJ QJ o(h   ^ `OJQJo(h ^`OJQJo(oh !!^!`OJ QJ o(h 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJ QJ o(h ^`OJQJo(oh pp^p`OJ QJ o(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJ QJ o(h88^8`OJ QJ o(hHh ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o( ^`OJ QJ o( ^`OJQJo(o   ^ `OJ QJ o(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJ QJ o( ^`OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJ QJ o( pp^p`OJQJo(o @ @ ^@ `OJ QJ o( ^`OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( PP^P`OJQJo(o   ^ `OJ QJ o(h ^`OJ QJ o(h ^`OJQJo(oh pp^p`OJ QJ o(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJ QJ o( ^`OJQJo(o ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h TT^T`OJQJo(h $ $ ^$ `OJQJo(oh   ^ `OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh dd^d`OJ QJ o(h 44^4`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h^`OJ QJ o(hH ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h^`OJ QJ o(hH ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o( ^`OJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o( ^`OJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h^`OJ QJ o(hH ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o( ^`OJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(n n ^n `o()  ^ `.xLx^x`L.HH^H`.^`.L^`L.^`.^`.X LX ^X `L.h88^8`OJ QJ o(hHh ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJ QJ o( ^`OJQJo( ^`OJQJo(o PP^P`OJ QJ o(h88^8`OJ QJ o(hHh ^`OJQJo(oh   ^ `OJ QJ o(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh ^`OJ QJ o(#(]U{`})yx\dUg}H:yp&85 up?May`j&&D9?`oeZ eK{ S"!6 'SQ;e$=qu0Z CDX7yK4M)yxZ"^+W>{h*X 2##hGM!?Uqm24@GGGG'@Unknown G.Cx Times New Roman5Symbol3. *Cx Arial9Garamond?. x@Arial BlackI Arial Unicode MS5. .[`)Tahoma7.@Calibri?= *Cx Courier New;WingdingsA$BCambria Math"1hgg66!z4##2qHP?m2! xx joekProduction Operation#                           ! " Oh+'0|  8 D P\dltjoek Normal.dotmProduction Operation2Microsoft Office Word@@ʐI@ʐI՜.+,0 hp  Zacks Investment Research6#  Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$)Root Entry Fd^I+Data `1TablemWordDocumentSummaryInformation(DocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q